{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T11:15:10Z","timestamp":1774350910646,"version":"3.50.1"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2021,5,25]],"date-time":"2021-05-25T00:00:00Z","timestamp":1621900800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,5,25]],"date-time":"2021-05-25T00:00:00Z","timestamp":1621900800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Internist"],"published-print":{"date-parts":[[2021,6]]},"DOI":"10.1007\/s00108-021-01046-5","type":"journal-article","created":{"date-parts":[[2021,5,25]],"date-time":"2021-05-25T09:02:58Z","timestamp":1621933378000},"page":"611-619","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Toxizit\u00e4ten nach Chim\u00e4rer-Antigenrezeptor-T-Zell-Therapie","Toxicity after chimeric antigen receptor T-cell therapy"],"prefix":"10.1007","volume":"62","author":[{"given":"Jorge","family":"Garcia Borrega","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katrin","family":"Heindel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasemin","family":"G\u00f6reci","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Clemens","family":"Warnke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Oezguer A.","family":"Onur","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthias","family":"Kochanek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Natalie","family":"Schub","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francis","family":"Ayuk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dominic","family":"Wichmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Boris","family":"B\u00f6ll","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,5,25]]},"reference":[{"key":"1046_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/S0140-6736(20)31366-0","volume":"6736","author":"JS Abramson","year":"2020","unstructured":"Abramson\u00a0JS, Palomba\u00a0ML, Gordon\u00a0LI et al (2020) Lisocabtagene maraleucel for patients with relapsed or refractory large B\u2011cell lymphomas (TRANSCEND NHL 001): a\u00a0multicentre seamless design study. Lancet 6736:1\u201314. https:\/\/doi.org\/10.1016\/S0140-6736(20)31366-0","journal-title":"Lancet"},{"key":"1046_CR2","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2020.38.15_suppl.8505","author":"JG Berdeja","year":"2020","unstructured":"Berdeja\u00a0JG, Madduri\u00a0D, Usmani\u00a0SZ et al (2020) Update of CARTITUDE-1: a phase Ib\/II study of JNJ-4528, a\u00a0B-cell maturation antigen (BCMA)-directed CAR-T-cell therapy, in relapsed\/refractory multiple myeloma. J\u00a0Clin Oncol. https:\/\/doi.org\/10.1200\/jco.2020.38.15_suppl.8505","journal-title":"J Clin Oncol"},{"key":"1046_CR3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1804980","author":"SJ Schuster","year":"2018","unstructured":"Schuster\u00a0SJ, Bishop\u00a0MR, Tam\u00a0CS et al (2018) Tisagenlecleucel in adult relapsed or refractory diffuse large B\u2011cell lymphoma. N\u00a0Engl J Med. https:\/\/doi.org\/10.1056\/NEJMoa1804980","journal-title":"N Engl J Med"},{"key":"1046_CR4","doi-asserted-by":"publisher","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","volume":"377","author":"SS Neelapu","year":"2017","unstructured":"Neelapu\u00a0SS, Locke\u00a0FL, Bartlett\u00a0NL et al (2017) Axicabtagene ciloleucel CAR T\u2011cell therapy in refractory large B\u2011cell lymphoma. N\u00a0Engl J Med 377:2531\u20132544. https:\/\/doi.org\/10.1056\/NEJMoa1707447","journal-title":"N Engl J Med"},{"key":"1046_CR5","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1056\/nejmoa1914347","volume":"382","author":"M Wang","year":"2020","unstructured":"Wang\u00a0M, Munoz\u00a0J, Goy\u00a0A et al (2020) KTE-X19 CAR T\u2011cell therapy in relapsed or refractory mantle-cell lymphoma. N\u00a0Engl J Med 382:1331\u20131342. https:\/\/doi.org\/10.1056\/nejmoa1914347","journal-title":"N Engl J Med"},{"key":"1046_CR6","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.02103","author":"C Jacobson","year":"2020","unstructured":"Jacobson\u00a0C, Hunter\u00a0B, Redd\u00a0R et al (2020) Axicabtagene ciloleucel in the non-trial setting: outcomes and correlates of response, resistance, and toxicity. J\u00a0Clin Oncol. https:\/\/doi.org\/10.1200\/JCO.19.02103","journal-title":"J Clin Oncol"},{"key":"1046_CR7","unstructured":"Common Terminology Criteria for Adverse Events: 14.06.2010. https:\/\/evs.nci.nih.gov\/ftp1\/CTCAE\/CTCAE_4.03\/CTCAE_4.03_2010-06-14_QuickReference_8.5x11.pdf"},{"key":"1046_CR8","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1182\/blood-2014-05-552729","volume":"124","author":"DW Lee","year":"2014","unstructured":"Lee\u00a0DW, Gardner\u00a0R, Porter\u00a0DL et\u00a0al (2014) Current concepts in the diagnosis and management of cytokine release syndrome. Blood 124:188\u2013195. https:\/\/doi.org\/10.1182\/blood-2014-05-552729","journal-title":"Blood"},{"key":"1046_CR9","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","volume":"25","author":"DW Lee","year":"2019","unstructured":"Lee\u00a0DW, Santomasso\u00a0BD, Locke\u00a0FL et\u00a0al (2019) ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells. Biol Blood Marrow Transplant 25:625\u2013638. https:\/\/doi.org\/10.1016\/j.bbmt.2018.12.758","journal-title":"Biol Blood Marrow Transplant"},{"issue":"2","key":"1046_CR10","doi-asserted-by":"publisher","first-page":"e191","DOI":"10.1097\/HS9.0000000000000191","volume":"3","author":"J Garcia Borrega","year":"2019","unstructured":"Garcia Borrega J, G\u00f6del P, R\u00fcger MA, Onur \u00d6A, Shimabukuro-Vornhagen A, Kochanek M, B\u00f6ll B (2019) In the eye of the storm: immune-mediated toxicities associated with CAR\u2011T cell therapy. HemaSphere 3(2):e191","journal-title":"HemaSphere"},{"key":"1046_CR11","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-018-0343-9","author":"A Shimabukuro-Vornhagen","year":"2018","unstructured":"Shimabukuro-Vornhagen\u00a0A, G\u00f6del\u00a0P, Subklewe\u00a0M et al (2018) Cytokine release syndrome. J\u00a0Immunother Cancer. https:\/\/doi.org\/10.1186\/s40425-018-0343-9","journal-title":"J Immunother Cancer"},{"key":"1046_CR12","doi-asserted-by":"publisher","first-page":"1404","DOI":"10.1158\/2159-8290.CD-17-0698","volume":"7","author":"J Gust","year":"2017","unstructured":"Gust\u00a0J, Hay\u00a0KA, Hanafi\u00a0LA et al (2017) Endothelial activation and blood\u2013brain barrier disruption in neurotoxicity after adoptive immunotherapy with CD19 CAR\u2011T cells. Cancer Discov 7:1404\u20131419. https:\/\/doi.org\/10.1158\/2159-8290.CD-17-0698","journal-title":"Cancer Discov"},{"key":"1046_CR13","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1016\/j.cell.2020.08.022","volume":"183","author":"KR Parker","year":"2020","unstructured":"Parker\u00a0KR, Migliorini\u00a0D, Perkey\u00a0E et al (2020) Single-cell analyses identify brain mural cells expressing CD19 as potential off-tumor targets for CAR\u2011T immunotherapies. Cell 183:126\u2013142.e17. https:\/\/doi.org\/10.1016\/j.cell.2020.08.022","journal-title":"Cell"},{"key":"1046_CR14","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1158\/2159-8290.CD-17-1319","volume":"8","author":"BD Santomasso","year":"2018","unstructured":"Santomasso\u00a0BD, Park\u00a0JH, Salloum\u00a0D et al (2018) Clinical and biological correlates of neurotoxicity associated with car t\u2011cell therapy in patients with B\u2011cell acute lymphoblastic leukemia. Cancer Discov 8:958\u2013971. https:\/\/doi.org\/10.1158\/2159-8290.CD-17-1319","journal-title":"Cancer Discov"},{"key":"1046_CR15","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1007\/s00063-021-00780-w","volume":"116","author":"J Garcia Borrega","year":"2021","unstructured":"Garcia Borrega\u00a0J, Heindel\u00a0K, Kochanek\u00a0M et al (2021) Der kritisch kranke Patient nach CAR-T-Zell-Therapie. Med Klin Intensivmed Notfmed 116:121\u2013128. https:\/\/doi.org\/10.1007\/s00063-021-00780-w","journal-title":"Med Klin Intensivmed Notfmed"},{"key":"1046_CR16","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2018.11.002","author":"JN Brudno","year":"2019","unstructured":"Brudno\u00a0JN, Kochenderfer\u00a0JN (2019) Recent advances in CAR T\u2011cell toxicity: mechanisms, manifestations and management. Blood Rev. https:\/\/doi.org\/10.1016\/j.blre.2018.11.002","journal-title":"Blood Rev"},{"key":"1046_CR17","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2020.2703","author":"DB Rubin","year":"2020","unstructured":"Rubin\u00a0DB, Al Jarrah\u00a0A, Li\u00a0K et al (2020) Clinical predictors of neurotoxicity after chimeric antigen receptor T\u2011cell therapy. JAMA Neurol. https:\/\/doi.org\/10.1001\/jamaneurol.2020.2703","journal-title":"JAMA Neurol"},{"key":"1046_CR18","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1002\/hon.2595","volume":"37","author":"SS Neelapu","year":"2019","unstructured":"Neelapu\u00a0SS (2019) Managing the toxicities of CAR T\u2011cell therapy. Hematol Oncol 37:48\u201352. https:\/\/doi.org\/10.1002\/hon.2595","journal-title":"Hematol Oncol"},{"key":"1046_CR19","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1182\/blood.V130.Suppl_1.1547.1547","volume":"130","author":"FL Locke","year":"2017","unstructured":"Locke\u00a0FL, Neelapu\u00a0SS, Bartlett\u00a0NL et al (2017) Preliminary results of prophylactic tocilizumab after axicabtageneciloleucel (axi-cel; KTE-C19) treatment for patients with refractory, aggressive non-Hodgkin Lymphoma (NHL). Blood 130:1547","journal-title":"Blood"},{"key":"1046_CR20","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1007\/s00277-019-03622-0","volume":"98","author":"M Kochanek","year":"2019","unstructured":"Kochanek\u00a0M, Schalk\u00a0E, von Bergwelt-Baildon\u00a0M et al (2019) Management of sepsis in neutropenic cancer patients: 2018 guidelines from the infectious diseases working party (AGIHO) and intensive care working party (iCHOP) of the German society of hematology and medical oncology (DGHO). Ann Hematol 98:1051\u20131069. https:\/\/doi.org\/10.1007\/s00277-019-03622-0","journal-title":"Ann Hematol"},{"key":"1046_CR21","doi-asserted-by":"publisher","first-page":"eaau5907","DOI":"10.1126\/scitranslmed.aau5907","volume":"11","author":"K Mestermann","year":"2019","unstructured":"Mestermann\u00a0K, Giavridis\u00a0T, Weber\u00a0J et\u00a0al (2019) The tyrosine kinase inhibitor dasatinib acts as a\u00a0pharmacologic on\/off switch for CAR T cells. Sci Transl Med 11:eaau5907. https:\/\/doi.org\/10.1126\/scitranslmed.aau5907","journal-title":"Sci Transl Med"},{"key":"1046_CR22","doi-asserted-by":"publisher","DOI":"10.2217\/imt-2020-0116","author":"S Wei","year":"2020","unstructured":"Wei\u00a0S, Gu\u00a0R, Xu\u00a0Y et al (2020) Adjuvant ruxolitinib therapy relieves steroid-refractory cytokine-release syndrome without impairing chimeric antigen receptor-modified T\u2011cell function. Immunotherapy. https:\/\/doi.org\/10.2217\/imt-2020-0116","journal-title":"Immunotherapy"},{"issue":"24","key":"1046_CR23","doi-asserted-by":"publisher","first-page":"2149","DOI":"10.1182\/blood.2019001463","volume":"134","author":"RA Gardner","year":"2019","unstructured":"Gardner RA, Ceppi F, Rivers J, Annesley C, Summers C, Taraseviciute A, Gust J, Leger KJ, Tarlock K, Cooper TM, Finney OC, Brakke H, Li DH, Park JR, Jensen MC (2019) Preemptive mitigation of CD19 CAR T-cell cytokine release syndrome without attenuation of antileukemic efficacy. Blood 134(24):2149\u20132158. https:\/\/doi.org\/10.1182\/blood.2019001463","journal-title":"Blood"},{"key":"1046_CR24","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.jcrc.2020.04.008","volume":"58","author":"C Gutierrez","year":"2020","unstructured":"Gutierrez\u00a0C, Brown\u00a0ART, Herr\u00a0MM et al (2020) The chimeric antigen receptor-intensive care unit (CAR-ICU) initiative: surveying intensive care unit practices in the management of CAR T\u2011cell associated toxicities. J\u00a0Crit Care 58:58\u201364. https:\/\/doi.org\/10.1016\/j.jcrc.2020.04.008","journal-title":"J Crit Care"},{"key":"1046_CR25","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1007\/s00063-016-0202-8","volume":"111","author":"G Neitzke","year":"2016","unstructured":"Neitzke\u00a0G, Burchardi\u00a0H, Duttge\u00a0G et\u00a0al (2016) Grenzen der Sinnhaftigkeit von Intensivmedizin: Positionspapier der Sektion Ethik der DIVI. Med Klin Intensivmed Notfmed 111:486\u2013492. https:\/\/doi.org\/10.1007\/s00063-016-0202-8","journal-title":"Med Klin Intensivmed Notfmed"},{"key":"1046_CR26","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/S1470-2045(18)30864-7","volume":"20","author":"FL Locke","year":"2019","unstructured":"Locke\u00a0FL, Ghobadi\u00a0A, Jacobson\u00a0CA et al (2019) Long-term safety and activity of axicabtagene ciloleucel in refractory large B\u2011cell lymphoma (ZUMA-1): a\u00a0single-arm, multicentre, phase 1\u20132 trial. Lancet Oncol 20:31\u201342. https:\/\/doi.org\/10.1016\/S1470-2045(18)30864-7","journal-title":"Lancet Oncol"},{"key":"1046_CR27","doi-asserted-by":"publisher","first-page":"3776","DOI":"10.1182\/bloodadvances.2020002509","volume":"4","author":"T Jain","year":"2020","unstructured":"Jain\u00a0T, Knezevic\u00a0A, Pennisi\u00a0M et al (2020) Hematopoietic recovery in patients receiving chimeric antigen receptor T\u2011cell therapy for hematologic malignancies. Blood Adv 4:3776\u20133787. https:\/\/doi.org\/10.1182\/bloodadvances.2020002509","journal-title":"Blood Adv"},{"key":"1046_CR28","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.01467","author":"KM Cappell","year":"2020","unstructured":"Cappell\u00a0KM, Sherry\u00a0RM, Yang\u00a0JC et al (2020) Long-term follow-up of anti-CD19 chimeric antigen receptor T\u2011cell therapy. J\u00a0Clin Oncol. https:\/\/doi.org\/10.1200\/JCO.20.01467","journal-title":"J Clin Oncol"},{"key":"1046_CR29","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.bbmt.2019.08.003","volume":"26","author":"A Cordeiro","year":"2020","unstructured":"Cordeiro\u00a0A, Bezerra\u00a0ED, Hirayama\u00a0AV et al (2020) Late events after treatment with CD19-targeted chimeric antigen receptor modified T cells. Biol Blood Marrow Transplant 26:26\u201333. https:\/\/doi.org\/10.1016\/j.bbmt.2019.08.003","journal-title":"Biol Blood Marrow Transplant"}],"updated-by":[{"DOI":"10.1007\/s00108-021-01087-w","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2021,6,11]],"date-time":"2021-06-11T00:00:00Z","timestamp":1623369600000}}],"container-title":["Der Internist"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00108-021-01046-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00108-021-01046-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00108-021-01046-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,28]],"date-time":"2022-12-28T13:06:59Z","timestamp":1672232819000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00108-021-01046-5"}},"subtitle":["\u00dcbersicht und Management fr\u00fcher und verz\u00f6gerter Nebenwirkungen","Overview and management of early and late onset side effects"],"short-title":[],"issued":{"date-parts":[[2021,5,25]]},"references-count":29,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2021,6]]}},"alternative-id":["1046"],"URL":"https:\/\/doi.org\/10.1007\/s00108-021-01046-5","relation":{},"ISSN":["0020-9554","1432-1289"],"issn-type":[{"value":"0020-9554","type":"print"},{"value":"1432-1289","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5,25]]},"assertion":[{"value":"26 April 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 May 2021","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 June 2021","order":3,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Erratum","order":4,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Zu diesem Beitrag wurde ein Erratum ver\u00f6ffentlicht:","order":5,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s00108-021-01087-w","URL":"https:\/\/doi.org\/10.1007\/s00108-021-01087-w","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"J.\u00a0Garcia Borrega hat Reisekosten und Kongressgeb\u00fchren von Kite\/Gilead erhalten. C.\u00a0Warnke hat Honorare von Novartis, Biogen, Sanofi-Genzyme, Alexion, Janssen & Janssen und Roche erhalten. O.A.\u00a0Onur hat Honorare von Biogen erhalten. M.\u00a0Kochanek hat Honorare von Astellas, Gilead, MSD, Pfizer erhalten. N.\u00a0Schub hat Reisekosten und Kongressgeb\u00fchren von Kite\/Gilead, Novartis und Celgene\/BMS erhalten. F.\u00a0Ayuk hat Honorare von Novartis, Kite\/Gilead, Janssen und Celgene\/BMS erhalten. D.\u00a0Wichmann hat Honorare von Gilead, MSD, Pfizer und Shionogi erhalten. B.\u00a0B\u00f6ll hat Forschungsmittel und Honorare von Novartis, Kite\/Gilead, Miltenyi, Roche und Janssen & Janssen erhalten. K.\u00a0Heindel und Y.\u00a0G\u00f6reci geben an, dass kein Interessenkonflikt besteht.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autoren keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}